Plasma Metabolic Signatures of Healthy Overweight Subjects Challenged With an Oral Glucose Tolerance Test.
OGTT
dietary challenge test
insulin resistance
metabotypes
postprandial metabolism
Journal
Frontiers in nutrition
ISSN: 2296-861X
Titre abrégé: Front Nutr
Pays: Switzerland
ID NLM: 101642264
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
03
2022
accepted:
05
05
2022
entrez:
1
7
2022
pubmed:
2
7
2022
medline:
2
7
2022
Statut:
epublish
Résumé
Insulin secretion following ingestion of a carbohydrate load affects a multitude of metabolic pathways that simultaneously change direction and quantity of interorgan fluxes of sugars, lipids and amino acids. In the present study, we aimed at identifying markers associated with differential responses to an OGTT a population of healthy adults. By use of three metabolite profiling platforms, we assessed these postprandial responses of a total of 202 metabolites in plasma of 72 healthy volunteers undergoing comprehensive phenotyping and of which half enrolled into a weight-loss program over a three-month period. A standard oral glucose tolerance test (OGTT) served as dietary challenge test to identify changes in postprandial metabolite profiles. Despite classified as healthy according to WHO criteria, two discrete clusters (A and B) were identified based on the postprandial glucose profiles with a balanced distribution of volunteers based on gender and other measures. Cluster A individuals displayed 26% higher postprandial glucose levels, delayed glucose clearance and increased fasting plasma concentrations of more than 20 known biomarkers of insulin resistance and diabetes previously identified in large cohort studies. The volunteers identified by canonical postprandial responses that form cluster A may be called pre-pre-diabetics and defined as "at risk" for development of insulin resistance. Moreover, postprandial changes in selected fatty acids and complex lipids, bile acids, amino acids, acylcarnitines and sugars like mannose revealed marked differences in the responses seen in cluster A and cluster B individuals that sustained over the entire challenge test period of 240 min. Almost all metabolites, including glucose and insulin, returned to baseline values at the end of the test (at 240 min), except a variety of amino acids and here those that have been linked to diabetes development. Analysis of the corresponding metabolite profile in a fasting blood sample may therefore allow for early identification of these subjects at risk for insulin resistance without the need to undergo an OGTT.
Identifiants
pubmed: 35774538
doi: 10.3389/fnut.2022.898782
pmc: PMC9237474
doi:
Types de publication
Journal Article
Langues
eng
Pagination
898782Informations de copyright
Copyright © 2022 Fiamoncini, Donado-Pestana, Duarte, Rundle, Thomas, Kiselova-Kaneva, Gundersen, Bunzel, Trezzi, Kulling, Hiller, Sonntag, Ivanova, Brennan, Wopereis, van Ommen, Frost, Bell, Drevon and Daniel.
Déclaration de conflit d'intérêts
TG is the CEO and stockowner in Vitas Ltd. CD is a founder, stockowner, board member and consultant in Vitas Ltd. DS was an employee of biocrates life sciences AG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Lipid Res. 2015 Oct;56(10):2029-39
pubmed: 26239049
Gastroenterology. 1985 Nov;89(5):1070-7
pubmed: 3840109
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
Crit Rev Clin Lab Sci. 2018 Jan;55(1):21-32
pubmed: 29239245
Nutrients. 2018 Mar 30;10(4):
pubmed: 29601492
Am J Clin Nutr. 2015 May;101(5):1047-54
pubmed: 25787996
Nat Med. 2011 Apr;17(4):448-53
pubmed: 21423183
Am J Physiol Gastrointest Liver Physiol. 2017 Oct 1;313(4):G300-G312
pubmed: 28663304
Physiol Rev. 2021 Apr 1;101(2):683-731
pubmed: 32790577
PLoS One. 2013 Dec 16;8(12):e82459
pubmed: 24358186
Diabetologia. 2015 Oct;58(10):2324-35
pubmed: 26254576
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18745-50
pubmed: 19841271
Obesity (Silver Spring). 2012 Jan;20(1):76-87
pubmed: 21660078
FASEB J. 2015 Nov;29(11):4600-13
pubmed: 26198450
Metabolites. 2021 Jul 14;11(7):
pubmed: 34357347
Curr Opin Clin Nutr Metab Care. 2009 Mar;12(2):129-37
pubmed: 19202384
Mol Nutr Food Res. 2014 Jan;58(1):136-46
pubmed: 23847095
FEBS Lett. 2000 Nov 10;484(3):169-74
pubmed: 11078872
FASEB J. 2018 Oct;32(10):5447-5458
pubmed: 29718708
Trends Endocrinol Metab. 2022 Feb;33(2):120-135
pubmed: 34924221
Am J Clin Nutr. 1971 Jun;24(6):615-21
pubmed: 5581001
Mol Nutr Food Res. 2018 Mar;62(6):e1700756
pubmed: 29377510
Obesity (Silver Spring). 2013 Mar;21(3):E294-302
pubmed: 23404690
Sci Rep. 2018 Jun 6;8(1):8691
pubmed: 29875472
Obstet Gynecol Surv. 2004 Feb;59(2):141-54
pubmed: 14752302
Diabetes Care. 2003 Mar;26(3):868-74
pubmed: 12610051
Diabetes. 2012 Jun;61(6):1372-80
pubmed: 22511205
BMC Med. 2019 Nov 29;17(1):217
pubmed: 31779625
Diabetes. 2019 Sep;68(9):1730-1746
pubmed: 31167878
Diabetes. 2013 Feb;62(2):639-48
pubmed: 23043162
Ann N Y Acad Sci. 2018 Jan;1411(1):21-35
pubmed: 28868790
Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4233-E4240
pubmed: 28484010
Diabetes. 2013 Dec;62(12):4184-91
pubmed: 23884887
Nutrients. 2022 Jan 21;14(3):
pubmed: 35276829
Mol Nutr Food Res. 2020 May;64(9):e1901190
pubmed: 32170825
PLoS One. 2019 Sep 24;14(9):e0222815
pubmed: 31550292
Diabetol Metab Syndr. 2018 Dec 04;10:88
pubmed: 30534205
J Nutr. 2021 Oct 1;151(10):2868-2881
pubmed: 34255076
PLoS One. 2018 Jul 30;13(7):e0200908
pubmed: 30059528
Nat Rev Endocrinol. 2014 Aug;10(8):488-98
pubmed: 24821328
Nutrients. 2019 Dec 07;11(12):
pubmed: 31817857
J Diabetes Complications. 2018 Mar;32(3):266-270
pubmed: 29395839
Lancet. 1987 Dec 5;2(8571):1300-4
pubmed: 2890903
Am J Clin Nutr. 2019 Apr 1;109(4):1216-1223
pubmed: 30982858
Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1009-17
pubmed: 18765680
Cell Metab. 2017 Jan 10;25(1):43-56
pubmed: 28094011
Metabolomics. 2010 Sep;6(3):362-374
pubmed: 20676218
J Clin Endocrinol Metab. 2014 Apr;99(4):1442-51
pubmed: 24432996
J Diabetes Investig. 2017 Jul;8(4):489-495
pubmed: 28084015
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31825485
Nature. 2017 Feb 8;542(7640):177-185
pubmed: 28179656
Mol Cell Biol. 2001 Jul;21(14):4785-806
pubmed: 11416153
Curr Opin Lipidol. 2022 Feb 1;33(1):76-82
pubmed: 34907969
Nutrients. 2021 Jan 06;13(1):
pubmed: 33419065
Mol Metab. 2021 Oct;52:101261
pubmed: 34044180
J Proteome Res. 2006 Oct;5(10):2780-8
pubmed: 17022649
Endocrinology. 1998 Mar;139(3):832-7
pubmed: 9492010
FASEB J. 2012 Jun;26(6):2607-19
pubmed: 22426117
Endocrine. 2014 Apr;45(3):422-9
pubmed: 23934358
Adv Enzyme Regul. 1995;35:163-78
pubmed: 7572342
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Metabolism. 2003 Aug;52(8):1019-27
pubmed: 12898467
Int J Obes (Lond). 2021 Feb;45(2):331-336
pubmed: 32873909
J Clin Invest. 2011 Apr;121(4):1402-11
pubmed: 21403394
Diabetol Metab Syndr. 2018 Oct 05;10:74
pubmed: 30323862
PLoS One. 2013 Aug 22;8(8):e72890
pubmed: 23991163
J Clin Endocrinol Metab. 2016 Aug;101(8):3002-9
pubmed: 27270475